2.05
+0.025(+1.24%)
Currency In USD
| Previous Close | 2.02 |
| Open | 2.02 |
| Day High | 2.09 |
| Day Low | 1.97 |
| 52-Week High | 2.59 |
| 52-Week Low | 0.65 |
| Volume | 113,625 |
| Average Volume | 536,260 |
| Market Cap | 140.98M |
| PE | -1.1 |
| EPS | -1.86 |
| Moving Average 50 Days | 2.05 |
| Moving Average 200 Days | 1.34 |
| Change | 0.03 |
If you invested $1000 in Opus Genetics, Inc. (IRD) since IPO date, it would be worth $25,250 as of December 18, 2025 at a share price of $2.02. Whereas If you bought $1000 worth of Opus Genetics, Inc. (IRD) shares 1 year ago, it would be worth $1,565.89 as of December 18, 2025 at a share price of $2.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
GlobeNewswire Inc.
Dec 11, 2025 12:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in pa
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
GlobeNewswire Inc.
Dec 09, 2025 12:00 PM GMT
Initial favorable safety profile demonstrated in OPGx-BEST1 clinical trialRESEARCH TRIANGLE PARK, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company dev
Opus Genetics to Participate in Upcoming Investment Conferences
GlobeNewswire Inc.
Nov 20, 2025 1:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in pa